 "Moderna")
Moderna Inc said on Thursday it expects Covid-19 vaccine sales of $18.4 billion this year, above the $15 billion in sales forecast by Pfizer Inc for the only other vaccine authorized for emergency use in the United States so far.
Both vaccines, developed using a technology based on messenger RNA (mRNA), are being distributed at an unprecedented speed as cases mount in the United States, with deaths from Covid-19 surpassing the dire milestone of 500,000.
Moderna, whose shares rose 4 per cent to $150.7 in trading before the bell, has been aiming to ramp up production of the vaccine, its first and only revenue-generating product.
It now aims to produce at least 700 million doses this year and expects to raise production to as much as 1 billion doses by improving its manufacturing process..
"2020 demonstrated the power of harnessing mRNA to make medicines," Chief Executive Officer Stephane Bancel said in a statement.
Also Read
"I believe that 2021 will be an inflection year for Moderna."
Moderna expects cost of sales to be about 20% of product sales in 2021, well above the 4% it recorded a year earlier.
The company also said it had completed enrollment for a mid-to-late stage study of the vaccine in adolescents between the ages of 12 and 17, while a study in children aged six months to 11 years will start in the near-term.
Moderna's chief medical officer, Tal Zaks, would leave the company in late September, the company added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
